{"success":true,"data":{"pressRelease":{"id":"36313","rtpr_id":"nGNX2j64jT","ticker":"ANVS","exchange":"NYSE","all_tickers":["ANVS"],"title":"Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results","author":"Globe Newswire","published_at":"2026-05-15T11:30:00.727Z","article_body":"* Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in\nsummer 2026\n* PD open-label extension (OLE) study: 40% of patients enrolled; full\nenrollment on track in fourth quarter 2026\n* New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD\nis expected in early 2027 and as a potential disease-modifying treatment in\nearly 2028\nMALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS)\n(“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology\ncompany developing the investigational oral therapy, buntanetap, for\nneurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's\ndisease (PD), today provided business updates and reported financial results\nfor the first quarter ended March 31, 2026.\n\n\"We saw strong momentum across both our AD and PD programs in the first\nquarter,\" said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Our\nPhase 3 AD clinical trial achieved significant enrollment growth, keeping us\nfirmly on track to complete randomization of patients in summer 2026 and\ndeliver first top-line results in early 2027. Simultaneously, we launched a PD\nOLE study and have been encouraged by the robust interest from both returning\nand new patients. This year is pivotal: we expect to generate substantive\nclinical data across both indications that will anchor our regulatory path\ntoward an NDA submission for buntanetap.\"\n\nClinical highlights\n\nAlzheimer’s disease – pivotal Phase 3 trial (NCT06709014)\n* Enrollment: 85% of patients enrolled.\n* Screening: On May 15, 2026, Annovis closed enrollment to new participants\nafter reaching a sufficient number of patients in screening to meet the\ntrial's enrollment goal.\n* Safety: Annovis received a positive recommendation from the Data and Safety\nMonitoring Board (DSMB) regarding the drug’s safety at 6 months, supporting\nseamless continuation of the study.\n* Study design: The pivotal Phase 3 AD trial is recruiting early AD patients\npositive for pTau217 plasma biomarker. The study is designed to evaluate\nbuntanetap's symptomatic effect at 6 months and its potential\ndisease-modifying effect at 18 months.\nParkinson’s disease – OLE study (NCT07284784)\n* Enrollment: 40% of patients enrolled.\n* Skin biomarker: The PD OLE study is implementing a biomarker test measuring\nlevels of phosphorylated alpha-synuclein and nerve cell fiber density via skin\nbiopsy.\n* Digital biomarker: Annovis entered into a partnership with NeuroRPM to\nintegrate an AI-powered digital biomarker, enabling continuous, real-world\nassessment of motor functions in response to buntanetap.\n* Study design: The PD OLE study is designed to evaluate buntanetap's safety\nand long-term efficacy over the period of 36 months in participants from prior\nAnnovis’ trials as well as in new patients who had deep brain stimulation\n(DBS) surgery.\nCorporate highlights\n* Publications * Annovis published a byline article in The Scientist\n(https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274),\ntracing the 170-year scientific history of buntanetap, from the origins of its\npredecessor compound to its mechanism of action and key events that shaped the\ndrug’s clinical development.\n* Annovis announced a peer-reviewed publication of the Phase 2/3 AD clinical\ntrial results in Nature NPJ Dementia, available open access\n(https://www.nature.com/articles/s44400-026-00073-z), demonstrating a\ndose-dependent cognitive improvement and biomarker reductions in patients\ntreated with buntanetap. \n\n\n \n* Presentations\n * Cheng Fang, Ph.D., SVP, R&D, presented two posters at the AD/PD2026\nconference, highlighting clinical data which support buntanetap's treatment\neffect in PD with a particular focus on cognition and biomarker findings as\nwell as an update on the ongoing pivotal Phase 3 AD trial.\n* Maria Maccecchini, Ph.D., President and CEO, presented at Fierce Biotech\nWeek 2026 in Boston, delivering a talk titled \"The Multi-Protein Reality of\nAlzheimer's Disease: What the Science Has Known for Decades and What the Field\nHas Yet to Accept\n(https://www.fiercebiotechweek.com/event/fierce-biotech-week-2026/session/case-study-fireside-chat-0),\"\nmaking the scientific case for targeting multiple neurotoxic proteins in AD\nand presenting buntanetap's clinical evidence of cognitive and biomarker\nimprovements.\n\n\n \n* Patents\n * Annovis secured a U.S. patent, covering prevention and treatment of\nneurological injuries arising from brain infections through the administration\nof buntanetap or related compounds.\nUpcoming milestones\n* Phase 3 AD study: Annovis expects to reach full enrollment in summer 2026.\nThe symptomatic data readout is anticipated approximately 6 months after the\nlast patient is dosed. The disease-modifying data readout is anticipated 18\nmonths after the last patient is dosed.\n* PD OLE study: Annovis expects to complete enrollment for the PD OLE study in\nthe fourth quarter of 2026.\n* NDA pathway: Based on the Phase 3 AD study outcomes, Annovis plans to engage\nwith the FDA regarding a regulatory NDA submission for buntanetap as a\nsymptomatic treatment for AD in early 2027 and as a disease-modifying\ntreatment in early 2028.\nFinancial results\n* Annovis’ cash and cash equivalents totaled $14.2 million as of March 31,\n2026, compared to $19.5 million as of December 31, 2025. This excludes gross\nproceeds from its recent $10.0 million registered direct offering on April 10,\n2026. Annovis had 28.5 million shares of common stock outstanding as of March\n31, 2026.\n* Research and development expenses for the three months ended March 31, 2026,\nwere $16.7 million compared to $5.0 million for the three months ended March\n31, 2025.\n* General and administrative expenses for the three months ended March 31,\n2026, were $1.3 million compared to $1.3 million for the three months ended\nMarch 31, 2025.\n* Annovis reported a $0.63 basic and diluted net loss per common share for the\nthree months ended March 31, 2026, compared to a $0.32 basic and diluted net\nloss per common share for the three months ended March 31, 2025.\nAbout Annovis\nHeadquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a\nPhase 3 clinical-stage biotechnology company developing treatments for\nneurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's\ndisease (PD). The Company's lead drug candidate, buntanetap (formerly\nposiphen), is an investigational once-daily oral therapy that inhibits the\ntranslation of multiple neurotoxic proteins, including APP and amyloid beta,\ntau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism\nof action. By addressing the underlying causes of neurodegeneration, Annovis\naims to halt disease progression and improve cognitive and motor functions in\npatients. For more information, visit www.annovisbio.com and follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=O5R58MIdOXkDX_hVdfSYR6EjlWWSUwziREzBfs7B6YfPXSVFb64Aixd9QidUtJv1whuV1Lv3K1MPQKYbcl1vZXJ0Sz3Q-kQrnaCH3keUL9k-07zoJbcTn0-o6QyReEReEqxuwvGF4oSKczSFwJ9nWT-ioyYgyLBGzikU08cv6cPDfP5z3FJIR6_otmLATuIt5mjX0vm44ww6i9sJZKt5MIPSRVtbmXKQt0eq2fiaUBuVVB96W5_Fuu8w4tW4_eslEs2WikjTt_hpA7QhpLu7LpIdgjel8ZVKnliVIg7pgg8E4gG7pnsG-m6IkF2SWaR_), YouTube\n(https://www.globenewswire.com/Tracker?data=aXHOs_hK-3862DvgQgZS7g2JNxW-21_s_NuBIUlEWz2j_bY0xy-ncHWtBz-Vc_trCMlue_eZauIadjgU9srpW7xjoghEe38r88-VY-d3souisrNuHOtam1IxH1KVvCBIF831EpJRPFE0UQqv4yeS_bn-y3P1C2rbZxaX8WLmAJkSUxbTtpWpfi1WmW-lk-aH880tCFBwoA1txSrqpBb7P8HevWcNQq7SsrsWRh5eDEV8AIlnnPVtZtD_CbvvM29C),\nand X\n(https://www.globenewswire.com/Tracker?data=K2Qj24b_PZyz8bcB1HtsTnn3oKc1Pzh3_S4pHHKPdRT29lSROOvayKS3tRh4RgvOelpbjuYOKZ0mKWdhKq-JXyecHMjbbOshQyCq350jZhCXADrBL3Dld-P6NPnxizJ5zB3mM4_Js5pxY3WPVNS-pVo3QBhGbewcKZHpGcwG6tchfV6Q3nqOaZ20J5qJaSFyyv6Mmme5NrMuI69O_kmrsw==).\n\nInvestor Alerts\nInterested investors and shareholders are encouraged to sign up for press\nreleases and industry updates by registering for email alerts\nat https://www.annovisbio.com/email-alerts.\n\nForward-Looking Statements\nThis press release contains forward-looking statements under the Securities\nAct of 1933 and the Securities Exchange Act of 1934, as amended. Actual\nresults may differ due to various risks and uncertainties, including those\noutlined in the Company’s SEC filings under “Risk Factors” in its Annual\nReport on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes\nno obligation to update forward-looking statements except as required by law.\n\nContact Information:\nAnnovis Bio Inc.\n101 Lindenwood Drive\nSuite 225\nMalvern, PA 19355\nwww.annovisbio.com\n\nInvestor Contact:\nAlexander Morin, Ph.D.\nDirector, Strategic Communications\nAnnovis Bio\nir@annovisbio.com\n\n(Tables to follow)\n\n \n ANNOVIS BIO, INC. Balance Sheets \n \n March 31, \n 2026 December 31, \n (Unaudited) 2025 \n \n Assets \n Current assets: \n Cash and cash equivalents $ 14,219,081 $ 19,532,338 \n Prepaid expenses and other current assets 2,024,622 1,549,287 \n Total assets $ 16,243,703 $ 21,081,625 \n Liabilities and stockholders’ equity \n Current liabilities: \n Accounts payable $ 5,275,668 $ 2,590,516 \n Accrued expenses 7,514,977 1,044,859 \n Total current liabilities 12,790,645 3,635,375 \n Non-current liabilities: \n Warrant liability 327,000 595,000 \n Total liabilities 13,117,645 4,230,375 \n Commitments and contingencies (Note 6) \n Stockholders’ equity: \n Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — \n Common stock - $0.0001 par value, 70,000,000 shares authorized, 28,537,302 and 27,199,139 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 2,854 2,719 \n Additional paid-in capital 184,433,245 180,552,190 \n Accumulated deficit (181,310,041 ) (163,703,659 ) \n Total stockholders’ equity 3,126,058 16,851,250 \n Total liabilities and stockholders’ equity $ 16,243,703 $ 21,081,625 \n\n\n\n \n ANNOVIS BIO, INC. Statements of Operations \n \n Three Months Ended \n March 31, \n 2026 2025 \n Operating expenses: \n Research and development $ 16,720,362 $ 5,011,517 \n General and administrative 1,291,820 1,271,164 \n Total operating expenses 18,012,182 6,282,681 \n Operating loss (18,012,182 ) (6,282,681 ) \n Other income: \n Interest income 137,800 187,612 \n Change in fair value of warrants (Note 7) 268,000 558,000 \n Total other income, net 405,800 745,612 \n Net loss $ (17,606,382 ) $ (5,537,069 ) \n Net loss per share (Note 9) \n Basic $ (0.63 ) $ (0.32 ) \n Diluted $ (0.63 ) $ (0.32 ) \n Weighted-average number of common shares used in computing net loss per share \n Basic 27,847,884 17,431,234 \n Diluted 27,847,884 17,431,234 \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7ee459df-d33f-4f42-b27c-3bd20487d50c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2j64jT","title":"Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results","author":"Globe Newswire","ticker":"ANVS","created":"2026-05-15T11:30:00.727Z","tickers":["ANVS"],"exchange":"NYSE","article_body":"* Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in\nsummer 2026\n* PD open-label extension (OLE) study: 40% of patients enrolled; full\nenrollment on track in fourth quarter 2026\n* New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD\nis expected in early 2027 and as a potential disease-modifying treatment in\nearly 2028\nMALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS)\n(“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology\ncompany developing the investigational oral therapy, buntanetap, for\nneurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's\ndisease (PD), today provided business updates and reported financial results\nfor the first quarter ended March 31, 2026.\n\n\"We saw strong momentum across both our AD and PD programs in the first\nquarter,\" said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Our\nPhase 3 AD clinical trial achieved significant enrollment growth, keeping us\nfirmly on track to complete randomization of patients in summer 2026 and\ndeliver first top-line results in early 2027. Simultaneously, we launched a PD\nOLE study and have been encouraged by the robust interest from both returning\nand new patients. This year is pivotal: we expect to generate substantive\nclinical data across both indications that will anchor our regulatory path\ntoward an NDA submission for buntanetap.\"\n\nClinical highlights\n\nAlzheimer’s disease – pivotal Phase 3 trial (NCT06709014)\n* Enrollment: 85% of patients enrolled.\n* Screening: On May 15, 2026, Annovis closed enrollment to new participants\nafter reaching a sufficient number of patients in screening to meet the\ntrial's enrollment goal.\n* Safety: Annovis received a positive recommendation from the Data and Safety\nMonitoring Board (DSMB) regarding the drug’s safety at 6 months, supporting\nseamless continuation of the study.\n* Study design: The pivotal Phase 3 AD trial is recruiting early AD patients\npositive for pTau217 plasma biomarker. The study is designed to evaluate\nbuntanetap's symptomatic effect at 6 months and its potential\ndisease-modifying effect at 18 months.\nParkinson’s disease – OLE study (NCT07284784)\n* Enrollment: 40% of patients enrolled.\n* Skin biomarker: The PD OLE study is implementing a biomarker test measuring\nlevels of phosphorylated alpha-synuclein and nerve cell fiber density via skin\nbiopsy.\n* Digital biomarker: Annovis entered into a partnership with NeuroRPM to\nintegrate an AI-powered digital biomarker, enabling continuous, real-world\nassessment of motor functions in response to buntanetap.\n* Study design: The PD OLE study is designed to evaluate buntanetap's safety\nand long-term efficacy over the period of 36 months in participants from prior\nAnnovis’ trials as well as in new patients who had deep brain stimulation\n(DBS) surgery.\nCorporate highlights\n* Publications * Annovis published a byline article in The Scientist\n(https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274),\ntracing the 170-year scientific history of buntanetap, from the origins of its\npredecessor compound to its mechanism of action and key events that shaped the\ndrug’s clinical development.\n* Annovis announced a peer-reviewed publication of the Phase 2/3 AD clinical\ntrial results in Nature NPJ Dementia, available open access\n(https://www.nature.com/articles/s44400-026-00073-z), demonstrating a\ndose-dependent cognitive improvement and biomarker reductions in patients\ntreated with buntanetap. \n\n\n \n* Presentations\n * Cheng Fang, Ph.D., SVP, R&D, presented two posters at the AD/PD2026\nconference, highlighting clinical data which support buntanetap's treatment\neffect in PD with a particular focus on cognition and biomarker findings as\nwell as an update on the ongoing pivotal Phase 3 AD trial.\n* Maria Maccecchini, Ph.D., President and CEO, presented at Fierce Biotech\nWeek 2026 in Boston, delivering a talk titled \"The Multi-Protein Reality of\nAlzheimer's Disease: What the Science Has Known for Decades and What the Field\nHas Yet to Accept\n(https://www.fiercebiotechweek.com/event/fierce-biotech-week-2026/session/case-study-fireside-chat-0),\"\nmaking the scientific case for targeting multiple neurotoxic proteins in AD\nand presenting buntanetap's clinical evidence of cognitive and biomarker\nimprovements.\n\n\n \n* Patents\n * Annovis secured a U.S. patent, covering prevention and treatment of\nneurological injuries arising from brain infections through the administration\nof buntanetap or related compounds.\nUpcoming milestones\n* Phase 3 AD study: Annovis expects to reach full enrollment in summer 2026.\nThe symptomatic data readout is anticipated approximately 6 months after the\nlast patient is dosed. The disease-modifying data readout is anticipated 18\nmonths after the last patient is dosed.\n* PD OLE study: Annovis expects to complete enrollment for the PD OLE study in\nthe fourth quarter of 2026.\n* NDA pathway: Based on the Phase 3 AD study outcomes, Annovis plans to engage\nwith the FDA regarding a regulatory NDA submission for buntanetap as a\nsymptomatic treatment for AD in early 2027 and as a disease-modifying\ntreatment in early 2028.\nFinancial results\n* Annovis’ cash and cash equivalents totaled $14.2 million as of March 31,\n2026, compared to $19.5 million as of December 31, 2025. This excludes gross\nproceeds from its recent $10.0 million registered direct offering on April 10,\n2026. Annovis had 28.5 million shares of common stock outstanding as of March\n31, 2026.\n* Research and development expenses for the three months ended March 31, 2026,\nwere $16.7 million compared to $5.0 million for the three months ended March\n31, 2025.\n* General and administrative expenses for the three months ended March 31,\n2026, were $1.3 million compared to $1.3 million for the three months ended\nMarch 31, 2025.\n* Annovis reported a $0.63 basic and diluted net loss per common share for the\nthree months ended March 31, 2026, compared to a $0.32 basic and diluted net\nloss per common share for the three months ended March 31, 2025.\nAbout Annovis\nHeadquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a\nPhase 3 clinical-stage biotechnology company developing treatments for\nneurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's\ndisease (PD). The Company's lead drug candidate, buntanetap (formerly\nposiphen), is an investigational once-daily oral therapy that inhibits the\ntranslation of multiple neurotoxic proteins, including APP and amyloid beta,\ntau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism\nof action. By addressing the underlying causes of neurodegeneration, Annovis\naims to halt disease progression and improve cognitive and motor functions in\npatients. For more information, visit www.annovisbio.com and follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=O5R58MIdOXkDX_hVdfSYR6EjlWWSUwziREzBfs7B6YfPXSVFb64Aixd9QidUtJv1whuV1Lv3K1MPQKYbcl1vZXJ0Sz3Q-kQrnaCH3keUL9k-07zoJbcTn0-o6QyReEReEqxuwvGF4oSKczSFwJ9nWT-ioyYgyLBGzikU08cv6cPDfP5z3FJIR6_otmLATuIt5mjX0vm44ww6i9sJZKt5MIPSRVtbmXKQt0eq2fiaUBuVVB96W5_Fuu8w4tW4_eslEs2WikjTt_hpA7QhpLu7LpIdgjel8ZVKnliVIg7pgg8E4gG7pnsG-m6IkF2SWaR_), YouTube\n(https://www.globenewswire.com/Tracker?data=aXHOs_hK-3862DvgQgZS7g2JNxW-21_s_NuBIUlEWz2j_bY0xy-ncHWtBz-Vc_trCMlue_eZauIadjgU9srpW7xjoghEe38r88-VY-d3souisrNuHOtam1IxH1KVvCBIF831EpJRPFE0UQqv4yeS_bn-y3P1C2rbZxaX8WLmAJkSUxbTtpWpfi1WmW-lk-aH880tCFBwoA1txSrqpBb7P8HevWcNQq7SsrsWRh5eDEV8AIlnnPVtZtD_CbvvM29C),\nand X\n(https://www.globenewswire.com/Tracker?data=K2Qj24b_PZyz8bcB1HtsTnn3oKc1Pzh3_S4pHHKPdRT29lSROOvayKS3tRh4RgvOelpbjuYOKZ0mKWdhKq-JXyecHMjbbOshQyCq350jZhCXADrBL3Dld-P6NPnxizJ5zB3mM4_Js5pxY3WPVNS-pVo3QBhGbewcKZHpGcwG6tchfV6Q3nqOaZ20J5qJaSFyyv6Mmme5NrMuI69O_kmrsw==).\n\nInvestor Alerts\nInterested investors and shareholders are encouraged to sign up for press\nreleases and industry updates by registering for email alerts\nat https://www.annovisbio.com/email-alerts.\n\nForward-Looking Statements\nThis press release contains forward-looking statements under the Securities\nAct of 1933 and the Securities Exchange Act of 1934, as amended. Actual\nresults may differ due to various risks and uncertainties, including those\noutlined in the Company’s SEC filings under “Risk Factors” in its Annual\nReport on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes\nno obligation to update forward-looking statements except as required by law.\n\nContact Information:\nAnnovis Bio Inc.\n101 Lindenwood Drive\nSuite 225\nMalvern, PA 19355\nwww.annovisbio.com\n\nInvestor Contact:\nAlexander Morin, Ph.D.\nDirector, Strategic Communications\nAnnovis Bio\nir@annovisbio.com\n\n(Tables to follow)\n\n \n ANNOVIS BIO, INC. Balance Sheets \n \n March 31, \n 2026 December 31, \n (Unaudited) 2025 \n \n Assets \n Current assets: \n Cash and cash equivalents $ 14,219,081 $ 19,532,338 \n Prepaid expenses and other current assets 2,024,622 1,549,287 \n Total assets $ 16,243,703 $ 21,081,625 \n Liabilities and stockholders’ equity \n Current liabilities: \n Accounts payable $ 5,275,668 $ 2,590,516 \n Accrued expenses 7,514,977 1,044,859 \n Total current liabilities 12,790,645 3,635,375 \n Non-current liabilities: \n Warrant liability 327,000 595,000 \n Total liabilities 13,117,645 4,230,375 \n Commitments and contingencies (Note 6) \n Stockholders’ equity: \n Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — \n Common stock - $0.0001 par value, 70,000,000 shares authorized, 28,537,302 and 27,199,139 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 2,854 2,719 \n Additional paid-in capital 184,433,245 180,552,190 \n Accumulated deficit (181,310,041 ) (163,703,659 ) \n Total stockholders’ equity 3,126,058 16,851,250 \n Total liabilities and stockholders’ equity $ 16,243,703 $ 21,081,625 \n\n\n\n \n ANNOVIS BIO, INC. Statements of Operations \n \n Three Months Ended \n March 31, \n 2026 2025 \n Operating expenses: \n Research and development $ 16,720,362 $ 5,011,517 \n General and administrative 1,291,820 1,271,164 \n Total operating expenses 18,012,182 6,282,681 \n Operating loss (18,012,182 ) (6,282,681 ) \n Other income: \n Interest income 137,800 187,612 \n Change in fair value of warrants (Note 7) 268,000 558,000 \n Total other income, net 405,800 745,612 \n Net loss $ (17,606,382 ) $ (5,537,069 ) \n Net loss per share (Note 9) \n Basic $ (0.63 ) $ (0.32 ) \n Diluted $ (0.63 ) $ (0.32 ) \n Weighted-average number of common shares used in computing net loss per share \n Basic 27,847,884 17,431,234 \n Diluted 27,847,884 17,431,234 \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7ee459df-d33f-4f42-b27c-3bd20487d50c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-15T11:30:00.800706328Z","server_sent_at_ms":1778844600800},"received_at":"2026-05-15T11:30:00.873Z","source_url":null},"analysis":{"id":"25758","press_release_id":"36313","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Cash balance of $14.2M (pre-April offering) suggests limited runway without further financing","R&D expenses tripled YoY, accelerating cash burn","Recent registered direct offering implies potential dilution and limited access to traditional capital markets"],"eventType":"earnings","narrative":"Annovis reported Q1 2026 results with a net loss of $17.6 million and EPS of -$0.63, driven by a surge in R&D expenses to $16.7 million from $5.0 million year-over-year.\n\nCash and cash equivalents stood at $14.2 million as of March 31, excluding $10 million in proceeds from a registered direct offering completed in April 2026.\n\nClinically, the pivotal Phase 3 Alzheimer’s trial reached 85% enrollment, with full enrollment expected in summer 2026 and top-line symptomatic data anticipated in early 2027.\n\nThe company also launched a Parkinson’s disease open-label extension study, which is 40% enrolled, and secured a new patent for neurological injury treatment.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Annovis hits key clinical milestones in Phase 3 AD trial but faces near-term cash constraints with only $14M on hand pre-offering."},"keyFigures":{"revenue":0,"customDimensions":{"ga_expenses":1291820,"rd_expenses":16720362,"shares_outstanding":28537302,"cash_and_equivalents":14219081,"pd_ole_enrollment_pct":"40%","ad_trial_enrollment_pct":"85%"}},"quotedText":"This year is pivotal: we expect to generate substantive clinical data across both indications that will anchor our regulatory path toward an NDA submission for buntanetap.","namedEntities":{"people":[{"name":"Maria Maccecchini","role":"President and CEO"},{"name":"Cheng Fang","role":"SVP, R&D"},{"name":"Alexander Morin","role":"Director, Strategic Communications"}],"products":["buntanetap","posiphen"],"companies":[{"name":"Annovis Bio, Inc.","ticker":"ANVS"},{"name":"NeuroRPM","relationship":"partner"}],"dollarAmounts":[{"amount":"$14.2 million","context":"cash and cash equivalents as of March 31, 2026"},{"amount":"$19.5 million","context":"cash and cash equivalents as of December 31, 2025"},{"amount":"$10.0 million","context":"gross proceeds from registered direct offering on April 10, 2026"},{"amount":"$16.7 million","context":"R&D expenses for Q1 2026"},{"amount":"$5.0 million","context":"R&D expenses for Q1 2025"},{"amount":"$1.3 million","context":"G&A expenses for Q1 2026"},{"amount":"$0.63","context":"net loss per share for Q1 2026"},{"amount":"$0.32","context":"net loss per share for Q1 2025"}]},"materialImpact":{"score":3,"reasoning":"The release combines Q1 financial results (showing a widening loss and low cash balance) with positive clinical trial updates (85% enrollment in pivotal Phase 3 AD trial). The financials are bearish due to cash burn, but the clinical progress is bullish for the long-term thesis."},"tickerRelevance":{"others":[{"ticker":"N/A","relevance":"partner"}],"primary":"ANVS"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"clinical_progress_and_financials","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"mixed","material_impact_score":3,"narrative":"Annovis reported Q1 2026 results with a net loss of $17.6 million and EPS of -$0.63, driven by a surge in R&D expenses to $16.7 million from $5.0 million year-over-year.\n\nCash and cash equivalents stood at $14.2 million as of March 31, excluding $10 million in proceeds from a registered direct offering completed in April 2026.\n\nClinically, the pivotal Phase 3 Alzheimer’s trial reached 85% enrollment, with full enrollment expected in summer 2026 and top-line symptomatic data anticipated in early 2027.\n\nThe company also launched a Parkinson’s disease open-label extension study, which is 40% enrolled, and secured a new patent for neurological injury treatment.","key_figures":{"revenue":0,"customDimensions":{"ga_expenses":1291820,"rd_expenses":16720362,"shares_outstanding":28537302,"cash_and_equivalents":14219081,"pd_ole_enrollment_pct":"40%","ad_trial_enrollment_pct":"85%"}},"named_entities":{"people":[{"name":"Maria Maccecchini","role":"President and CEO"},{"name":"Cheng Fang","role":"SVP, R&D"},{"name":"Alexander Morin","role":"Director, Strategic Communications"}],"products":["buntanetap","posiphen"],"companies":[{"name":"Annovis Bio, Inc.","ticker":"ANVS"},{"name":"NeuroRPM","relationship":"partner"}],"dollarAmounts":[{"amount":"$14.2 million","context":"cash and cash equivalents as of March 31, 2026"},{"amount":"$19.5 million","context":"cash and cash equivalents as of December 31, 2025"},{"amount":"$10.0 million","context":"gross proceeds from registered direct offering on April 10, 2026"},{"amount":"$16.7 million","context":"R&D expenses for Q1 2026"},{"amount":"$5.0 million","context":"R&D expenses for Q1 2025"},{"amount":"$1.3 million","context":"G&A expenses for Q1 2026"},{"amount":"$0.63","context":"net loss per share for Q1 2026"},{"amount":"$0.32","context":"net loss per share for Q1 2025"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-15T11:32:08.409Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"clinical_progress_and_financials","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":29497,"modelName":"george-droid-qwen-72b"}}